Document is current

Article History

Received: 4 June 2024

Revised: 12 September 2024

Accepted: 18 September 2024

First Online: 23 October 2024

Competing interests

: CS, SE, IM, YS, EP, DRB, RT, RMB, AdM, AR, AB, FLF, PG, CV, JC, DR, BP, VvdN declare no competing interest. BC received a grant from the Lopez Albo Post-residency Program of the Hospital Universitario Marqués de Valdecilla, financed by Servicio Cántabro de Salud (PESI/1/23). AGdL reports the following conflicts of interest: Consulting: AstraZeneca, Bayer, Bristol Myers Squibb, Ipsen, Johnson & Johnson, Merck, KGaA, MSD, Pfizer and Roche; and research funding (institution) from AstraZeneca, Genmab A/S, Gilead, Jansen-Cilag, Medsir, Merck, KGaA, MSD, Roche and Syneos Health. PG declares the following conflicts of interest: Consulting: MSD, Bristol Myers Squibb, AstraZeneca, EMD Serono, Seagen, Pfizer, Janssen, Roche, Astellas Pharma, Gilead Sciences, Silverback Therapeutics, BostonGene, Fresenius Kabi, Lucence Health, PureTech, G1 Therapeutics, Aadi Biosciences, CG Oncology, Strata Oncology, ImmunityBio, Asieris Pharmaceuticals, AbbVie, Bicycle Therapeutics; Institutional research funding: Pfizer, Bristol Myers Squibb, MSD, QED Therapeutics, GlaxoSmithKline, Mirati Therapeutics, EMD Serono, G1 Therapeutics, Gilead Sciences, Acrivon Therapeutics, ALX Oncology, Genentech. ID reports the following financial competing interests: Advisory role for ASTELLAS, Bristol Myers Squibb, Immunomedics, Inc., Ipsen, MSD and Roche Genentech. Steering Committee Member for Immunomedics, Inc. Invited Speaker for Astellas, Bayer, Bristol Myers Squibb, EUSA PHARMA, IPSEN, Jansen, Merck, MSD, Novartis and PFIZER. MERCK, Astra Zeneca and BAYER covered expenses related to conference visits. Grant support from Astra Zeneca and ROCHE GENENTECH. ID is PI of an investigator-initiated trial funded by GILEAD and sponsored by the foundation of the department (FUPOCAN). MvdH declares the following competing interests: consultation (paid to institute) for AstraZeneca, BMS, Roche / Genentech, Astellas, Seattle Genetics, Pfizer, MSD, and Janssen; grant support (to institute) from BMS, AstraZeneca, Roche, MSD and 4SC.

: This study (Irbd22-147) was approved by the NKI-AVL Institutional Review Board, a tailor-made reviewing board for research with human data. As this concerns a retrospective study, no formal informed consent was required.